Overview

A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects

Status:
RECRUITING
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
Assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization for healthy subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.
Treatments:
(2-(1R)-1-cyclopropyl)ethyl-6-isopropyl-phenol
HSK3486
Moxifloxacin